Cargando…
p53 mutations have no additional prognostic value over stage in bladder cancer.
Evidence is accumulating that the tumour-suppressor gene p53 is involved in the development of bladder cancer. Therefore we studied p53 mutations in 47 bladder cancers obtained from 45 patients using polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) analysis. Eight out of...
Autores principales: | Vet, J. A., Bringuier, P. P., Poddighe, P. J., Karthaus, H. F., Debruyne, F. M., Schalken, J. A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033347/ https://www.ncbi.nlm.nih.gov/pubmed/8080737 |
Ejemplares similares
-
p16 mutations/deletions are not frequent events in prostate cancer.
por: Tamimi, Y., et al.
Publicado: (1996) -
A retrospective study of high mobility group protein I(Y) as progression marker for prostate cancer determined by in situ hybridization.
por: Tamimi, Y., et al.
Publicado: (1996) -
An Update of the Interstitial Cell Compartment in the Normal Human Bladder
por: Kuijpers, Kamiel A. J., et al.
Publicado: (2014) -
p53 mutations in urinary bladder cancer
por: Berggren, P, et al.
Publicado: (2001) -
The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group.
por: Kiemeney, L. A., et al.
Publicado: (1993)